Transcutaneous Pulsed Radiofrequency Targeting the Tibial Nerve Versus Radial Extracorporeal Shock Wave Therapy for Painful Calcaneal Spur: a Randomized Controlled Trial
Heel pain is a common musculoskeletal complaint that can substantially impair daily activities and reduce patients' quality of life. Calcaneal spurs are frequently associated with plantar heel pain, although the presence of a spur does not necessarily indicate that it is the direct source of symptoms. Treatment is generally conservative and may include activity modification, stretching exercises, orthoses, analgesics, and physical therapy modalities. However, some patients continue to experience symptoms despite these interventions.
Extracorporeal shock wave therapy (ESWT) is an established non-invasive treatment option for persistent plantar heel pain and plantar fasciopathy. It delivers acoustic pressure waves to the target tissue and is thought to exert its therapeutic effects through mechanotransduction, vascular responses, tissue remodeling, and modulation of nociceptive signaling.
Pulsed radiofrequency (PRF) is a neuromodulatory technique that delivers intermittent radiofrequency energy while limiting thermal tissue damage. Its proposed mechanisms include modulation of nociceptive transmission and neural signaling rather than intentional nerve destruction. Transcutaneous pulsed radiofrequency (TCPRF) provides a non-invasive approach by delivering radiofrequency energy through surface electrodes, without the need for needle insertion.
Although radiofrequency-based interventions and ESWT have been investigated separately in patients with painful calcaneal spurs and plantar heel pain, clinical evidence regarding TCPRF targeting the posterior tibial nerve remains limited. This randomized controlled trial compared the effects of TCPRF applied over the posterior tibial nerve with radial ESWT in patients with symptomatic calcaneal spurs. Pain intensity, foot-related function, and analgesic consumption were evaluated over a three-month follow-up period.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This prospective, single-center, randomized controlled trial was conducted between September 2024 and April 2025 in the Pain Medicine and Physical Medicine and Rehabilitation departments of the University of Health Sciences Istanbul Kanuni Sultan Suleyman Training and Research Hospital. A total of 55 patients aged 18-65 years with symptomatic, radiologically confirmed calcaneal spurs who had not responded adequately to conservative treatment were enrolled.
Following confirmation of eligibility and provision of written informed consent, participants were assigned to one of two treatment groups using a computer-generated randomization sequence: the TCPRF group (n = 29) or the radial ESWT group (n = 26). The sample size calculation was performed using G*Power version 3.1.9.4, with a two-sided significance level of 0.05, statistical power of 90%, and an effect size of 0.85 based on pain intensity data from a previous randomized trial of TCPRF. The calculated minimum sample sizes were 28 participants for the TCPRF group and 24 for the ESWT group.
In the TCPRF group, treatment was administered by an experienced pain medicine specialist under standard monitoring, including non-invasive blood pressure measurement, pulse oximetry, and electrocardiography. Participants were placed in the supine position. A 45 × 98 mm transcutaneous electrode (FIAB SPA, Italy) was positioned at the ankle, posterior to the medial malleolus, along the course of the posterior tibial nerve and adjacent to the posterior tibial artery, which was identified by palpation. TCPRF was delivered at 80 V, 2 Hz, and a pulse duration of 20 ms for 8 minutes. The treatment was administered once weekly for a total of three sessions.
In the ESWT group, radial extracorporeal shock wave therapy was delivered using an electro-pneumatic device (Vibrolith Orto®). All sessions were administered by the same physiotherapist under the supervision of a physical medicine and rehabilitation specialist with at least 10 years of experience in ESWT prescription. Participants were positioned prone, and radial shock waves were applied to the calcaneal spur region using the following parameters: 10 Hz, 2,000 impulses, and 2.5 bar. Treatment was administered once weekly for a total of three sessions.
Participants in both groups received standardized instructions regarding a home exercise program that included foot and plantar fascia stretching exercises. Paracetamol was permitted as the only rescue analgesic during the follow-up period; the use of other analgesics, including non-steroidal anti-inflammatory drugs, was discouraged.
Treatment outcomes were assessed by an independent pain medicine specialist who was blinded to treatment allocation. Demographic and clinical data, including age, sex, body mass index, symptom duration, comorbidities, concomitant medical treatments, and the treated side, were recorded at baseline. Pain intensity was assessed using the Visual Analogue Scale (VAS), a 10-cm scale ranging from 0 (no pain) to 10 (the worst pain imaginable). Participants were asked to indicate their average heel pain during the preceding week. Foot-related function was evaluated using the Foot Function Index (FFI), a validated 23-item questionnaire comprising three domains: pain, disability, and activity limitation. Higher FFI scores indicate greater functional impairment. Mean daily paracetamol consumption was also recorded in milligrams per day.
VAS scores, FFI scores, and daily paracetamol consumption were evaluated at baseline (T0), one month (T1), and three months (T3) after treatment. The FFI was prespecified as the primary outcome, while VAS pain scores and mean daily paracetamol consumption were considered secondary outcomes.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Istanbul, Turquía (Türkiye), 34000
- Kanuni Sultan Süleyman Training and Research Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria
Patients aged 18-65 years.
Patients diagnosed with calcaneal spur based on medical history, clinical examination, and radiological findings, who had not responded adequately to conservative treatment.
Patients who provided written informed consent to participate in the study.
Exclusion Criteria
Patients who had undergone any interventional procedure for calcaneal spur within the preceding 6 months.
Patients with morbid obesity (body mass index > 35 kg/m²).
Patients with advanced decompensated heart failure or an implanted cardiac pacemaker.
Patients with a known allergy to transcutaneous electrodes or pads.
Patients with skin infection at the ESWT application site or the transcutaneous electrode placement site.
Patients with metal implants.
Patients with circulatory disorders or skin lesions in the treatment area.
Patients unable to communicate adequately or maintain the required treatment position.
Patients with bleeding disorders.
Patients with active psychosis, progressive neurological deficits, or neuromuscular disorders.
Pregnant women.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Otro: Neuromodulación del nervio tibial posterior en el espolón calcáneo (Epin Calcanei)
|
Instead of invasive application of PRF directly to the lesion area or nerve, transcutaneous pulsed radiofrequency (TCPRF) is applied noninvasively. |
|
Otro: Terapia de ondas de choque extracorpóreas (ESWT)
|
A shock wave is created together with sound and pressure waves. Changes at the cellular level with the shock wave include increased collagen production, increased blood flow in the applied area, acceleration of wound healing and cellular proliferation. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Visual Analogue Scale
Periodo de tiempo: three months
|
three months
|
|
Foot Function Index
Periodo de tiempo: three months
|
three months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: halil ibrahim altun, specialist, Kanuni Sultan Süleyman Training and Research Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- heelspur
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .